Fever Clinical Trial
Official title:
An Exploratory Study of the Genetics, Pathophysiology, and Natural History of Autoinflammatory Diseases
NCT number | NCT00001373 |
Other study ID # | 940105 |
Secondary ID | 94-HG-0105 |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | March 10, 1994 |
This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older. Patients will undergo a medical and family history, physical examination, blood and urine tests. Additional tests and procedures may include the following: 1. X-rays 2. Consultations with specialists 3. DNA sample collection (blood or saliva sample) for genetic studies. These might include studies of specific genes, or more complete sequencing of the genome. 4. Additional blood samples a maximum of 1 pint (450 ml) during a 6-week period for studies of white cell adhesion (stickiness) 5. Leukapheresis for collecting larger amounts of white cells for study. For this procedure, whole blood is collected through a needle in an arm vein. The blood flows through a machine that separates it into its components. The white cells are removed and the rest of the blood is returned to the body through another needle in the other arm. Patients may be followed approximately every 6 months to monitor symptoms, adjust medicine dosages, and undergo routine blood and urine tests. They will receive genetic counseling by the study team on the risk of having affected children and be advised of treatment options. Participating relatives will undergo a medical and family history, possibly with a review of medical records, physical examination, blood and urine tests. Additional procedures may include a 24-hour urine collection, X-rays, and consultations with medical specialists. A DNA sample (blood or saliva) will also be collected for genetic studies. Additional blood samples of no more than 550 mL during an 8-week period may be requested for studies of white cell adhesion (stickiness). Relatives who have familial Mediterranean fever, TRAPS, or hyper-IgD syndrome will receive the same follow-up and counseling as described for patients above. Normal volunteers and patients with gout will have a brief health interview and check of vital signs (blood pressure and pulse) and will provide a blood sample (up to 90 ml, or 6 tablespoons). Additional blood samples of no more than 1 pint over a 6-week period may be requested in the future.
Status | Recruiting |
Enrollment | 5000 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 2 Months to 115 Years |
Eligibility | - INCLUSION CRITERIA: There are three populations that will be included in this study: subjects with known or suspected autoinflammatory diseases, family members of subjects with known or suspected autoinflammatory diseases, and healthy controls. In order to be eligible to participate in this study as a subject with known or suspected autoinflammatory disease, an individual must meet all of the following criteria: 1. Stated willingness to participate in study procedures (which at the very least includes providing a mail-in sample for genetic analysis); 2. Regardless of gender, at least one month of age; 3. A medical history that, in the expert opinion of the study team, is consistent with the possibility of autoinflammatory disease; and 4. Ability of the subject, parents (in the case of children), or Legally Authorized Representative to understand and the willingness to sign a written informed consent document. In order to be eligible to participate in this study as a family member of a subject with known or suspected autoinflammatory disease, an individual must meet all of the following criteria: 1. Stated willingness to participate in study procedures (which at the very least includes providing a mail-in sample for genetic analysis); 2. Regardless of gender, at least one month of age; 3. Relationship, either by blood or marriage, to an individual enrolled or about to be enrolled in the study with known or suspected autoinflammatory disease; 4. Likelihood, in the expert opinion of the study team, that analysis of a sample from the individual would advance genetic or functional analysis of the affected relative s possible autoinflammatory condition; and 5. Ability of the subject, parents (in the case of children), or Legally Authorized Representative to understand and the willingness to sign a written informed consent document. In order to be eligible to participate in this study as a healthy volunteer, an individual must meet all of the following criteria: 1. Stated willingness to participate in study procedures for healthy volunteers; 2. Regardless of gender, at least one year old, and not pregnant (by history of a missed menstrual period); 3. Likelihood, in the expert opinion of the study team, that a sample from the individual would advance the functional analysis of an autoinflammatory condition under study; and 4. Ability of the subject or parents (in the case of children) to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: For any of the three categories of subjects, an individual will be excluded from participation in this study if he or she has a medical condition that would, in the opinion of the investigators, confuse the interpretation of the study. |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins University | Baltimore | Maryland |
United States | National Institutes of Health Clinical Center | Bethesda | Maryland |
United States | Walter Reed National Medical Center | Bethesda | Maryland |
United States | University of Pittsburgh | Pittsburgh | Pennsylvania |
United States | Childrens National Medical Center | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
National Human Genome Research Institute (NHGRI) | Duke University, Merck Sharp & Dohme LLC, University of Massachusetts, Worcester |
United States,
Aksentijevich I, Kastner DL. Genetics of monogenic autoinflammatory diseases: past successes, future challenges. Nat Rev Rheumatol. 2011 Jul 5;7(8):469-78. doi: 10.1038/nrrheum.2011.94. — View Citation
Bulua AC, Mogul DB, Aksentijevich I, Singh H, He DY, Muenz LR, Ward MM, Yarboro CH, Kastner DL, Siegel RM, Hull KM. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum. 2012 Mar;64(3):908-13. doi: 10.1002/art.33416. — View Citation
Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, Barron KS, Weisman MH, Pashinian N, Reiff AO, Samuels J, Wright DA, Kastner DL, Lovell DJ. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012 Oct 16;157(8):533-41. doi: 10.7326/0003-4819-157-8-201210160-00003. Erratum In: Ann Intern Med. 2014 Feb 18;160(4):291-2. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Genetic linkage in autoinflammatory dise | discovery of genetic associations to autoinflammatory disorders | annually |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03706599 -
Fever Infants and Therapeutic Education in Emergency Department
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Not yet recruiting |
NCT01782183 -
Thermographic Characteristics of Sore Throat by Thermographic Camera
|
N/A | |
Withdrawn |
NCT00800696 -
Preventive Oral Care
|
N/A | |
Completed |
NCT02689193 -
IDIS Project Work Package 2: Establishing a Biobank at ITM and Collaborating Centres
|
||
Completed |
NCT02212990 -
The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine
|
N/A | |
Completed |
NCT01869699 -
Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults
|
Phase 4 | |
Completed |
NCT01911143 -
A Retrospective, Blinded Validation of a Host-response Based Diagnostics
|
N/A | |
Completed |
NCT01559675 -
Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery
|
N/A | |
Completed |
NCT01194557 -
Introducing Rapid Diagnostic Tests Into the Private Health Sector
|
N/A | |
Completed |
NCT00940654 -
The Fever and Antipyretic in Critically Illness Evaluation Study
|
N/A | |
Completed |
NCT00969176 -
Pharmacokinetics, -Dynamics and Safety of Intravenous Paracetamol in Neonates
|
Phase 2/Phase 3 | |
Recruiting |
NCT00729976 -
Oral Versus Rectal Ibuprofen for Fever in Young Children - a Randomized Control Study.
|
Phase 4 | |
Recruiting |
NCT00389272 -
Adding a Second Drug for Febrile Children Treated With Acetaminophen
|
N/A | |
Completed |
NCT00257790 -
The Tobramycin Study
|
Phase 4 | |
Recruiting |
NCT05033613 -
Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease
|
||
Completed |
NCT02595827 -
Non-inferiority Trial of Conditional vs Universal Follow up for Children With Fever in Democratic Republic of Congo
|
Phase 3 | |
Recruiting |
NCT06061575 -
Comparison of the Efficacy of Paracetamol and Ibuprofen in the Management of Fever in Sepsis Patients
|
Phase 4 | |
Recruiting |
NCT06038617 -
Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children
|
Phase 4 |